Okayama, Japan

Hirofumi Kunitake

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Nagase Viita Co., Ltd.. Active years: 2025.


% Patents Active = 100.0


Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Hirofumi Kunitake: Innovator in Crystalline Potassium Salt

Introduction

Hirofumi Kunitake is a notable inventor based in Okayama, Japan. He has made significant contributions to the field of chemistry, particularly in the development of novel compounds. His work focuses on enhancing the properties of ascorbic acid derivatives, which have various applications in health and nutrition.

Latest Patents

Hirofumi Kunitake holds a patent for the "Crystalline potassium salt of 2-O-α-D-glucosyl-L-ascorbic acid and method for producing the same." This invention aims to provide a novel crystalline form of 2-O-α-D-glucosyl-L-ascorbic acid, along with a method for its production. The innovation addresses the need for improved stability and efficacy of ascorbic acid derivatives in various applications.

Career Highlights

Kunitake's career is marked by his dedication to research and development in the field of chemistry. He has successfully developed a unique crystalline form of a vital compound, showcasing his expertise and innovative thinking. His work has the potential to impact various industries, including pharmaceuticals and food science.

Collaborations

Hirofumi Kunitake has collaborated with talented individuals such as Osamu Sano and Akiko Miyake. These partnerships have fostered a creative environment that encourages the exchange of ideas and advancements in their respective fields.

Conclusion

Hirofumi Kunitake is a distinguished inventor whose work on crystalline potassium salt of 2-O-α-D-glucosyl-L-ascorbic acid exemplifies innovation in chemistry. His contributions continue to pave the way for advancements in health and nutrition applications.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…